Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.41 USD
Change Today +0.01 / 2.50%
Volume 188.1K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

immunocellular therapeutics (IMUC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $1.04
52 Week Low
08/24/15 - $0.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immunocellular therapeutics (IMUC) Related Bloomberg News

View More Bloomberg News

immunocellular therapeutics (IMUC) Related Businessweek News

No Related Businessweek News Found

immunocellular therapeutics (IMUC) Details

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

5 Employees
Last Reported Date: 03/10/15

immunocellular therapeutics (IMUC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.1K
Founder, Chairman, Chief Scientific Officer a...
Total Annual Compensation: $161.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $207.1K
Senior Vice President of Strategic Resources
Total Annual Compensation: $400.3K
Compensation as of Fiscal Year 2014.

immunocellular therapeutics (IMUC) Key Developments

ImmunoCellular Mulls Acquisitions

ImmunoCellular Therapeutics, Ltd. (AMEX:IMUC) intends to pursue acquisitions. ImmunoCellular issued a letter to its shareholders. The letter says, "While ICT-107 advances through phase 3, we intend to generate a pipeline of programs from this exciting technology and potentially from other adjacent technologies we are evaluating for in-license or acquisition. We also are working to evaluate options for continued financing of the phase 3 trial. Finally, our board, focused on identifying and appointing qualified candidates, intends to remedy our non-compliance with the NYSE policies on the proportion of independent board members and the constitution of our Audit Committee."

ImmunoCellular Therapeutics Receives Non-Compliance Notice From NYSE MKT

On August 14, 2015, ImmunoCellular Therapeutics, Ltd. received a letter from NYSE MKT LLC (NYSE MKT) notifying the Company that it is not in compliance with the continued listing standards set forth under Sections 802(a) and 803(B)(2)(a) of the NYSE MKT Company Guide. The foregoing Sections require a listed company to maintain a majority of independent directors on its Board of Directors and at least three independent directors on the Company’s Audit Committee. The Company is deficient in meeting these standards as a result of Richard Chin’s resignation as a director of the Company and a member of the Audit Committee, effective as of June 26, 2015. As previously disclosed on its Form 8-K filed with the Securities and Exchange Commission on April 14, 2015, Mr. Chin notified the Company that he would not stand for re-election as a director at the Company’s 2015 Annual Meeting of Stockholders, held on June 26, 2015. According to Sections 802(b) and 803(B)(6)(b) of the Company Guide and as set forth in the Letter, the Company will have until the earlier of its next annual stockholders’ meeting or one year from the occurrence of the event that caused the failure to comply with Sections 802(a) and 803(B)(2)(a) of the Company Guide to regain compliance. A below compliance indicator will be disseminated as an extension of the Company’s trading symbol commencing five (5) business days following receipt of the Letter. The indicator will be removed when the Company has regained compliance with all applicable continued listing standards. The Company has commenced its search for a candidate to fill in the vacancy resulting from the director resignation and will endeavor to complete the process and appoint such replacement to the Board of Directors and the Audit Committee as soon as practicable.

ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment for ICT-107 Phase 3 Registrational Trial in Glioblastoma

ImmunoCellular Therapeutics, Ltd. announced that it has reached agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma. The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of about 400 HLA-A2 positive subjects, which will be conducted at about 120 sites in the US, Canada and the EU. The primary endpoint in the trial is overall survival, which the FDA and EU regulators have stated is the appropriate endpoint for registrational clinical studies in glioblastoma. Secondary endpoints include progression-free survival and safety, as well as overall survival in the two pre-specified MGMT subgroups. Patient enrollment is anticipated to begin in the late third quarter or early fourth quarter of 2015. A Special Protocol Assessment is a written agreement between the sponsor company and the FDA on the design, clinical endpoints, size and statistical design of a clinical trial intended to form the primary basis of an efficacy claim in the marketing application, such as a biologic licensing application (BLA) or a new drug application (NDA). Final marketing approval depends upon the safety and efficacy results demonstrated in the phase 3 clinical program.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUC:US $0.41 USD +0.01

IMUC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUC.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMUC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCELLULAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at